Novelpharm finances itself through private equity. New capital is used for product developments, further developments and studies. This enables Novelpharm to secure its innovative edge, bring promising products to market quickly and expand its product pipeline in a targeted manner.
As soon as products subject to approval have reached a certain stage of development, they are to be out-licensed both in Switzerland and abroad to renowned pharmaceutical companies that have the relevant experience and distribution infrastructure in Switzerland and in the major international markets. Over-the-counter products will be marketed in the Swiss home market and also out-licensed abroad.
Out-licensing enables Novelpharm to remain lean and efficient, to focus on product development and to generate sales quickly. For pharmaceutical companies, in turn, Novelpharm is an attractive partner to supplement their often dried-up product pipelines.
Novelpharm offers private investors a medium-term investment opportunity with attractive potential. A regular personal exchange is maintained with larger investors. Further information is available via
